Everything you need to win EXICURE, INC. — in one platform.
Who to reach, what to say, and why now on EXICURE, INC. — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on EXICURE, INC. — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Exicure Achieves First Milestone in License Agreement with GPCR Therapeutics
Jan 22, 2026•5 months ago
Contract Type
licensing
SkokieOtherBiotechnologyHealth CareTherapeutics
Description
Exicure, Inc. has completed Milestone 1 under its License and Collaboration Agreement with GPCR Therapeutics Inc. This milestone pertains to the completion of Exicure's Phase 2 clinical trial and involves a formal submission of the Clinical Study Report to the FDA. Following this achievement, the company is required to make a milestone payment of $1,000,000 to GPCR Therapeutics within 30 days
Company Information
Company
EXICURE, INC.
Location
8045 LAMON AVE, SUITE 410
Skokie, Illinois, United States
About
Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
SkokieOtherBiotechnologyHealth CareTherapeutics